Overview

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Status:
Completed

Trial end date:
2020-06-03

Target enrollment:

Participant gender:

Summary

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Antibodies, Monoclonal
Mirikizumab